Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆ - ESMO Open
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Changing Treatment Paradigm for ALK-Positive Lung Cancer - ILCN.org (ILCN/WCLC)
Kaplan-Meier estimates of progression-free survival (PFS) in the... | Download Scientific Diagram
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up | JACC: CardioOncology
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Cancers | Free Full-Text | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
ALK-positive NSCLC: updates on crizotinib and alectinib - memoinOncology
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Charu Aggarwal, MD, MPH on Twitter: "Final OS analysis of J-ALEX Alectinib vs Crizotinib ✴️ No significant OS difference BUT ✴️ Majority of patients crossed over to alectinib (~78%) @ALKLungCancer @alk_fusion @ASCO #
First-Line PFS - ALECENSA® (alectinib)
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer | SpringerLink
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study — ALK POSITIVE
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
